Please, Signup (Login) to subscribe or trade (demo)
Stag Industrial stock price
Stag Industrial latest news:
Dow futures drop over 200 points a day after markets rebound
U.S. stock futures were dropping early Wednesday, a day after stocks staged a dramatic turnaround following a recent spate of extreme volatility for equities. Dow industrial futures fell 245 points, or 1%, to 24,550, while S&P 500 futures dropped 29.30 points, or 1.1%, to 2,665. Nasdaq-100 futures fell 79.25 points, or 1.2%, to 6,574.25. The decline in stock futures came as a strong rebound for Asia equities appeared to fade. The Dow industrials rallied 567 points on Tuesday, reversing that exact same point fall seen at the open. The turnaround came after the index's worst one-day point decline in history on Monday. The Dow, S&P 500 and Nasdaq Composite returned to positive territory for the year after Tuesday's action. Oil futures moved modestly higher, while gold inched up and the ICE Dollar Index was holding steady.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Cerus shares rise on positive late-stage results for anemia therapy
Cerus Corp. shares rose 17.6% in Wednesday trade after the company said a late-stage clinical trial evaluating the company's Intercept treatment for chronic anemia in patients with the inherited blood disorder thalassemia had positive results. In the phase 3 trial, which enrolled 86 patients, individuals with Intercept-treated red blood cells met the trial's primary efficacy and safety endpoints, the company said. The company plans to file for commercialization in Europe in the second half of this year. Cerus shares have surged 77.4% over the last three months, compared with a 10.5% rise in the S&P 500 and a 11.8% rise in the Dow Jones Industrial Average .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
GE's stock turns lower after disclosure of SEC probe into insurance reserve increase
Shares of General Electric Co. turned lower in premarket trade Wednesday, after Chief Financial Officer Jamie Miller said in the industrial conglomerate's post-earnings conference call with analysts that the Securities and Exchange Commission was investigating the process that led to the large insurance reserve increase announced last week, according to a transcript provided by FactSet. Miller said the SEC was also looking into GE's revenue recognition and controls for long-term service agreements. Miller said the company is "cooperating fully" with the investigation, which she said is still in "the very early stages." The stock fell 0.5% in premarket trade, after being up as much as 5% after the company reported fourth-quarter results. The stock has tumbled 22.8% over the past three months through Tuesday, while the Dow Jones Industrial Average has climbed 10.5%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
AveXis could be lifted by rival Spark Therapeutics' pricing scheme for gene therapy: RBC
Biotech AveXis Inc. could benefit, if indirectly, from payment arrangements set up by rival Spark Therapeutics Inc. for its $850,000-a-patient gene therapy Luxturna, RBC Capital Markets analyst Brian Abrahams said on Wednesday. AveXis, which is developing its AVXS-101 gene therapy as a one-time treatment for spinal muscular atrophy, saw shares decline 3.6% in heavy Wednesday trade. AVXS-101, if approved, could cost as much as $2 million per treatment, Abrahams said. The payment schemes set up by Spark, intended to make Luxturna's record-setting pricetag more palatable to health care payers, "helps set the stage for AVXS's '101 and other gene therapies," Abrahams said. "We note this strategy is in distinct contrast to what had taken place with other one-time treatments as in HCV, and believe that this more proactive approach is more likely to ensure the buy-in of key constituents (rather than generate a backlash)." Positive results from a phase 1 trial of AVXS-101 were published in the New England Journal of Medicine in November, and Abrahams said that the Food and Drug Administration might consider accelerated approval. Abrahams also raised his price target for AveXis from $97 to $99 on Wednesday, citing the success of Biogen's spinal muscular atrophy therapy Spinraza, among other factors. AveXis shares have surged 8.4% over the last three months, compared with a 6.9% rise in the S&P 500 and a 9.6% rise in the Dow Jones Industrial Average .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Biogen price target raised 20% to $420 at Instinet, citing 'meaningful 2018 for the company'
Biogen Inc.'s price target was raised 18% to $420 by Instinet on Thursday, citing its expectation of "a meaningful 2018 for the company." The price target increase comes as Biogen shares have slid 3% after a negative analysis was released for one of its Alzheimer's disease drug trials. Instinet analyst Christopher Marai, however, noted high hopes for the company's spinal muscular atrophy therapy Spinraza, agreements Biogen has with companies like Alkermes and Eisai and the company's much-anticipated other Alzheimer's disease drug, aducanumab. "In our view, potentially positive catalysts from BIIB's both widely covered and underappreciated mid- to late-stage pipeline assets (which we do not yet include in our own estimates) will not only be stock-moving but also index-moving, making BIIB 'a must own name.'" Biogen shares have risen 2.6% over the last three months to $323.23, compared with a 7.5% rise in the S&P 500 and a 10.6% rise in the Dow Jones Industrial Average .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
UPDATE: Revance stock surges and Allergan drops on positive results for wrinkle injection
Revance Therapeutics Inc. shares surged nearly 38% in extremely heavy morning trade Tuesday after the company reported positive results for its wrinkle-relaxing injection in two late-stage clinical trials. If approved, the product, DaxibotulinumtoxinA for Injection (RT002), would be the first of its kind to last six months. Products currently on the market, including Allergan's market-leading Botox, last three to four months. Allergan shares dropped 3.2% in extremely heavy morning trade on Tuesday. In two trials, Revance's product showed highly statistically significant improvement relative to the placebo in reducing frown lines or wrinkles between eyebrows. The product is also being tested in a long-term safety trial, with results expected in the second half of next year; if the trial is successfully completed, Revance expects to file for approval in the first half of 2019 and, if it's approved, launch the product in the U.S. in 2020. Botox has been a wildly profitable product for Allergan, since patients largely pay out-of-pocket for it, and analysts have noted that new rivals could pose a long-term risk for the company. Revance's latest data are "better than their Ph 2 on several metrics," said EvercoreISI analyst Umer Raffat. But, with regard to being able to claim six months of effectiveness, Raffat said, "I think there's a case to be made for that, but that's not a layup." Raffat also noted that the product would likely be priced higher than Botox. In a statement to MarketWatch, Allergan called the Revance results "underwhelming." "Allergan does not expect Revance's toxin to enter the market until mid-2020, and we do not believe this data will support a longer duration claim," a company spokesperson said, adding that "based on the profile demonstrated in this data, Allergan does not view this toxin as being differentiated from Botox." Revance shares have surged 45.5% over the last three months to $35.80, compared with a 7.4% rise in the S&P 500 and a 11.7% rise in the Dow Jones Industrial Average .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Galectin Therapeutics stock drops nearly 50% after negative trial results
Galectin Therapeutics Inc. shares dropped nearly 50% in premarket trade on Tuesday after the company said its GR-MD-02 therapy did not meet its primary endpoint in a midstage clinical trial. The company emphasized, however, that the therapy reduced the primary endpoint in a statistically significant and "clinically meaningful" way, relative to the placebo, in about half of the patients in the clinical trial. Results were not statistically significant in the total group of patients "because there was more variability in HVPG measurements for patients with esophageal varices," the company said. Galectin Chief Executive Peter Traber said that the results "stratify a large and easily identifiable group of patients" and "suggest several potential registration endpoints that may be employed in a phase 3 program." GR-MD-02 is being developed for nonalcoholic steatohepatitis, or NASH, a common disease that is caused by fat buildup in the liver and can cause inflammation and damage there. Drugmakers have been racing to capture the market, which they expect to be worth billions of dollars. Galectin shares have surged 42.4% over the last three months to $2.48, compared with a 7.4% rise in the S&P 500 and a 11.7% rise in the Dow Jones Industrial Average .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
StanCorp Financial GroupSFG
Standard Motor ProductsSMP
Standard Pacific CorpSPF
Standex International CorporationSXI
Stanley Black & DeckerSWH
Stanley Black & DeckerSWJ
Stanley Black & DeckerSWK
Stanley Black & DeckerSWU